



BTC secures exclusive distribution rights for Alteco LPS Adsorber® from Alteco Medical

BTC health (ASX:BTC) is pleased to announce its investee company, BiolImpact Pty Ltd, has secured exclusive distribution rights from Alteco Medical AB (Spotlight Stock Exchange, Stockholm) for Alteco LPS Adsorber® in Australia and New Zealand.

Alteco LPS Adsorber® is an innovative, safe, single-use medical product, used to treat sepsis or septic shock in patients with suspected or confirmed septicaemia caused by gram-negative bacteria. It is used as an extracorporeal filter, typically in the ICU environment where a critically ill patient has been placed on haemoperfusion. The unique matrix design, optimised surface area and proprietary components of the LPS Adsorber actively bind circulating endotoxins, removing them from the patient's bloodstream. A new sterile filter is used for each treatment which lasts approximately 2 hours. A reduction in endotoxin levels is usually associated with less of an immune system "over-reaction", and an improvement in patient haemodynamic parameters and clinical outcomes.

The Alteco LPS Adsorber® is a Class IIa medical device with CE approval and it has been available in select global markets since 2007. BTC Speciality Health intends to make a submission to the Therapeutic Goods Association (TGA) for product registration, and on grant of marketing approval, will make the Alteco LPS Adsorber available to Australian hospitals in early 2023.

"We are confident that our partnership with BTC health will be successful over time and is an important step in our quest in offering an effective way of minimising the horrible effects of sepsis, ultimately saving lives" says Alteco Medical CEO Fredrik Jonsson.

Sepsis is a time-critical medical emergency that arises when the body's response to an infection damages its own tissues and organs leading to failure of multiple organs, and death if not recognised and not treated promptly. National inpatient data shows that sepsis cases are increasing in Australia. The Australian Sepsis Network reports that almost 5,000 of an estimated 18,000 Australians treated in an intensive care unit die each year as a result of sepsis.¹ Sepsis imposes significant economic burdens on the healthcare system and individuals with an estimated cost per case of \$39,300.²

Dr. Richard Treagus, Executive Chairman commented "We believe that LPS Adsorber is a great example of a high-quality, novel product that has the potential to make a real difference to patient outcomes. This is an exciting addition to our growing product portfolio and our sales team is well positioned in the hospital critical care space to support the introduction of the Alteco LPS Adsorber in the months ahead."

Further information on Alteco Medical and Alteco LPS Adsorber® can be obtained via <https://altecomed.com>

¹ <https://www.safetyandquality.gov.au/our-work/national-sepsis-program>

² <https://www.australiansepsisnetwork.net.au/healthcare-providers/sepsis-epidemiology>

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of BTC health to be materially different from the statements in this announcement.

About BTC Health

BTC health Ltd ("BTC") is a Pooled Development Fund which makes active investments in businesses that acquire, develop and distribute innovative medical products in Australia and New Zealand. The company is building a group of high-growth businesses which together are focused on providing access to some of the best specialised therapeutics and medical devices from around the world. BTC is listed on the Australian Stock Exchange (Code: BTC). Additional information can be found at www.btchealth.com.au

About Alteco Medical AB

Alteco Medical AB from Lund, Sweden is an ISO 13485 certified medical device company founded in 2002. It offers a unique technology for blood purification during extracorporeal treatment. Its solution for extracorporeal endotoxin elimination helps hospitals manage endotoxemia and sepsis in the ICU, and to avoid these conditions post-operatively. Its product Alteco LPS Adsorber counteracts sepsis by removing the threat: endotoxin. Endotoxin is the initial trigger of the inflammatory response in the immune system and high levels of endotoxin are associated with organ failure and death. Inside the Alteco LPS Adsorber, a tailor-made synthetic peptide binds to Lipid A; the toxic part of endotoxin (lipopolysaccharides, LPS). By adsorbing harmful levels of endotoxin from the patient's bloodstream, the Alteco LPS Adsorber breaks the chain of immune system over-reactions that can spiral into sepsis and septic shock. Alteco LPS Adsorber is the only class IIa, CE-marked medical device for specific endotoxin adsorption. It is safely used to stabilize the patient's hemodynamic parameters with no contraindications, no reported side effects, or serious adverse events. The product is available on the global market since 2007 through an extensive network of local distributors.

Authorisation

This announcement was authorised for release by Dr. Richard Treagus, Chairman.

Contact Information

Richard Treagus
Chairman
BTC health Limited
Ph: +61 417 520 509
E-mail: rtreagus@btchealth.com.au

Sharon Papworth
Company Secretary
BTC health Limited
Ph: 1800 100 282
E-mail: spapworth@btchealth.com.au